KIF5B- EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma

Hui Xu; Chuan Shao

doi:10.2147/OTT.S263994

KIF5B- EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma

Onco Targets Ther. 2020 Aug 20:13:8317-8321. doi: 10.2147/OTT.S263994. eCollection 2020.

Authors

Hui Xu¹, Chuan Shao^{1

2

3}

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, People's Republic of China.
² Department of Special Procurement Ward, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.
³ Department of General Practice, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.

Abstract

With the rapid development of detection methods, next-generation sequencing (NGS) technology as a new technology, some novel epidermal growth factor receptor (EGFR) gene fusions comprising the EGFR linked to various fusion partners, most commonly RAD51, are detected in the non-small cell lung cancer (NSCLC). We described a case of an unreported kinesin family member 5B (KIF5B)-EGFR in NSCLC and the efficacy of EGFR tyrosine kinase inhibitors (TKIs) to this specific fusion. Considering this rare EGFR fusion and remarkable response to EGFR-TKI, we should realize the importance of these rare EGFR fusions, the advances in diagnostic techniques and personalized care for lung cancer patients.

Keywords: EGFR-TKIs; KIF5B-EGFR; adenocarcinoma; next-generation sequencing; non-small cell lung cancer.

Publication types

Case Reports